Five things for pharma marketers to know: Tuesday, May 24, 2016

1. Samsung Bioepis said its biosimilar version of Johnson & Johnson's Remicade was accepted for review by the FDA. Samsung began selling a biosimilar version of Pfizer's Enbrel this year in Europe. (WSJ)

2. GlaxoSmithKline said that its study testing Breo, its inhaled chronic obstructive pulmonary disease medicine, fared better than the standard of care. GSK said Breo showed a significant reduction in serious breathing difficulties in patients with COPD. (Reuters)

3. Sanofi rejiggered its executive committee. Pascale Witz, the company's EVP of diabetes and cardiovascular, will leave the company and will be replaced by Peter Guenter. Witz was tapped to lead the diabetes portfolio just five months ago. The French drugmaker also created a new consumer healthcare business unit, the leader of which will be named at a later date.

4. Valeant CEO Joseph Papa said the company will consider selling some of its assets but shied away from saying Bausch & Lomb would be included in those assets, saying it was a “core franchise.” (Rochester Business Journal)

5. ICYMI: Novartis' heart-failure drug, Entresto, received a “class 1” recommendation from the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America, in jointly issued practice guidelines. Entresto is now recommended over ACE inhibitors in patients with heart failure who are tolerant to current drugs. (Reuters)